AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey

BackgroundAdequate information to patients on disease and therapies is important to improve lifestyle, adherence to treatments and outcomes.ObjectivesTo describe which are the main sources of information for patients with rheumatic diseases treated with subcutaneous (SC) biological drugs, which ones...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.1244-1245
Hauptverfasser: de Toro, F.J., Batlle, E., González, C.M., Cea-Calvo, L., Pérez-Calvo, M.A., Carmona, L.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1245
container_issue Suppl 2
container_start_page 1244
container_title Annals of the rheumatic diseases
container_volume 75
creator de Toro, F.J.
Batlle, E.
González, C.M.
Cea-Calvo, L.
Pérez-Calvo, M.A.
Carmona, L.
description BackgroundAdequate information to patients on disease and therapies is important to improve lifestyle, adherence to treatments and outcomes.ObjectivesTo describe which are the main sources of information for patients with rheumatic diseases treated with subcutaneous (SC) biological drugs, which ones they consider relevant, and their satisfaction with the information received from the clinical team.MethodsRHEU-LIFE was a survey to patients >18 years with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with SC biological drugs, from 50 rheumatology outpatient clinics from Spain. The patients completed the survey anonymously at home. They selected from a list: 1) their sources of general information on disease (multiple choice), 2) the most important (one option), 3) who had informed them about the treatment alternatives (multiple choice) and 4) about the SC biological drug (multiple choice).ResultsThe survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years [SD 13.2], 42.4% men, 57.6% women). The main source of general information on disease was the rheumatologist (92.3%). Other sources mentioned were the primary care physician (21.7%), nurses (19.3%), medical websites (19.8%) or health related blogs (5.6%), brochures for patients (11.5%), friends or relatives (6.3%), patient associations (4.4%) or other patients (3.1%) and pharmacists (3.4%). Information about treatment options and the SC biological drug came mainly from the rheumatologist (>90%) and infrequently from nurses or hospital pharmacists (Table). 46.1% mentioned having received only oral information, 6.0% only written and 45.2% both ways. Some 44.5% and 42.6% reported to be “very satisfied” and “satisfied” with the information received respectively, 10.6% “neither satisfied nor dissatisfied” and 2.1% and 0.2% “dissatisfied” or “very dissatisfied”. 45.2% alleged to search for information about the biological treatment in sources other than the hospital clinical staff.Sources of information mentioned by patients (multiple choice)General info about treatmentSpecific info about the biologic drug(%)(%)Rheumatologist91.991.0Nurses10.217.9Hospital pharmacy3.211.5Others5.33.6Does not remember1.20.8No information received0.81.7ConclusionsThe rheumatologist is the main source of information for patients on SC biological drugs. Nurses and hospital pharmacists are seldom mentioned, even though being very often visited for drug dispensing. Satisfaction with the
doi_str_mv 10.1136/annrheumdis-2016-eular.3616
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901882099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322516017</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1279-6e9315622aa3bc6030bdd56fb4fb44d073cf3b2e30dbadda0f27cc50423e9d583</originalsourceid><addsrcrecordid>eNqVkE1Lw0AQhhdRsFb_w4Ln1Nlsuk3w1PoNBUXredmPiU1ps3U3UXLzIv5Pf4nb1oNXYWCYmfedYR5CThkMGOPiTNW1n2O7slVIUmAiwXap_IALJvZIj2Uij20B-6QHADzJCjE6JEchLGIJOct75Gs8YQDZ98fnk2u9wUBdSe_q0vmVaipX0-eAluqOPsQS6ybQ96qZ08fN1dgx9LIKqEL0zTyqJmq386dWm7ZRNbo20Enllu6lMmpJZ3P0at0NtguSaVVilPo37I7JQamWAU9-c588X1_NLm6T6f3N3cV4mmiWjopEYMHZUKSpUlwbARy0tUNR6ixGZmHETcl1ihysVtYqKNORMUPIUo6FHea8T053e9fevbYYGrmIf9fxpGQFsDxPoSii6nynMt6F4LGUa1-tlO8kA7khL_-QlxvycktebshHt9i59WrxL-MPVM-SGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901882099</pqid></control><display><type>article</type><title>AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey</title><source>BMJ Journals - NESLi2</source><creator>de Toro, F.J. ; Batlle, E. ; González, C.M. ; Cea-Calvo, L. ; Pérez-Calvo, M.A. ; Carmona, L.</creator><creatorcontrib>de Toro, F.J. ; Batlle, E. ; González, C.M. ; Cea-Calvo, L. ; Pérez-Calvo, M.A. ; Carmona, L.</creatorcontrib><description>BackgroundAdequate information to patients on disease and therapies is important to improve lifestyle, adherence to treatments and outcomes.ObjectivesTo describe which are the main sources of information for patients with rheumatic diseases treated with subcutaneous (SC) biological drugs, which ones they consider relevant, and their satisfaction with the information received from the clinical team.MethodsRHEU-LIFE was a survey to patients &gt;18 years with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with SC biological drugs, from 50 rheumatology outpatient clinics from Spain. The patients completed the survey anonymously at home. They selected from a list: 1) their sources of general information on disease (multiple choice), 2) the most important (one option), 3) who had informed them about the treatment alternatives (multiple choice) and 4) about the SC biological drug (multiple choice).ResultsThe survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years [SD 13.2], 42.4% men, 57.6% women). The main source of general information on disease was the rheumatologist (92.3%). Other sources mentioned were the primary care physician (21.7%), nurses (19.3%), medical websites (19.8%) or health related blogs (5.6%), brochures for patients (11.5%), friends or relatives (6.3%), patient associations (4.4%) or other patients (3.1%) and pharmacists (3.4%). Information about treatment options and the SC biological drug came mainly from the rheumatologist (&gt;90%) and infrequently from nurses or hospital pharmacists (Table). 46.1% mentioned having received only oral information, 6.0% only written and 45.2% both ways. Some 44.5% and 42.6% reported to be “very satisfied” and “satisfied” with the information received respectively, 10.6% “neither satisfied nor dissatisfied” and 2.1% and 0.2% “dissatisfied” or “very dissatisfied”. 45.2% alleged to search for information about the biological treatment in sources other than the hospital clinical staff.Sources of information mentioned by patients (multiple choice)General info about treatmentSpecific info about the biologic drug(%)(%)Rheumatologist91.991.0Nurses10.217.9Hospital pharmacy3.211.5Others5.33.6Does not remember1.20.8No information received0.81.7ConclusionsThe rheumatologist is the main source of information for patients on SC biological drugs. Nurses and hospital pharmacists are seldom mentioned, even though being very often visited for drug dispensing. Satisfaction with the information received is high, however nearly half said to have searched for information on the biological drug in alternative sources.AcknowledgementThis survey was financed by Merck Sharp &amp; Dohme of Spain and endorsed by the patient's association ConArtritis (Arthritis National Coordinator).Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.3616</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1244-1245</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1244.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1244.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3187,23562,27915,27916,77361,77392</link.rule.ids></links><search><creatorcontrib>de Toro, F.J.</creatorcontrib><creatorcontrib>Batlle, E.</creatorcontrib><creatorcontrib>González, C.M.</creatorcontrib><creatorcontrib>Cea-Calvo, L.</creatorcontrib><creatorcontrib>Pérez-Calvo, M.A.</creatorcontrib><creatorcontrib>Carmona, L.</creatorcontrib><title>AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey</title><title>Annals of the rheumatic diseases</title><description>BackgroundAdequate information to patients on disease and therapies is important to improve lifestyle, adherence to treatments and outcomes.ObjectivesTo describe which are the main sources of information for patients with rheumatic diseases treated with subcutaneous (SC) biological drugs, which ones they consider relevant, and their satisfaction with the information received from the clinical team.MethodsRHEU-LIFE was a survey to patients &gt;18 years with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with SC biological drugs, from 50 rheumatology outpatient clinics from Spain. The patients completed the survey anonymously at home. They selected from a list: 1) their sources of general information on disease (multiple choice), 2) the most important (one option), 3) who had informed them about the treatment alternatives (multiple choice) and 4) about the SC biological drug (multiple choice).ResultsThe survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years [SD 13.2], 42.4% men, 57.6% women). The main source of general information on disease was the rheumatologist (92.3%). Other sources mentioned were the primary care physician (21.7%), nurses (19.3%), medical websites (19.8%) or health related blogs (5.6%), brochures for patients (11.5%), friends or relatives (6.3%), patient associations (4.4%) or other patients (3.1%) and pharmacists (3.4%). Information about treatment options and the SC biological drug came mainly from the rheumatologist (&gt;90%) and infrequently from nurses or hospital pharmacists (Table). 46.1% mentioned having received only oral information, 6.0% only written and 45.2% both ways. Some 44.5% and 42.6% reported to be “very satisfied” and “satisfied” with the information received respectively, 10.6% “neither satisfied nor dissatisfied” and 2.1% and 0.2% “dissatisfied” or “very dissatisfied”. 45.2% alleged to search for information about the biological treatment in sources other than the hospital clinical staff.Sources of information mentioned by patients (multiple choice)General info about treatmentSpecific info about the biologic drug(%)(%)Rheumatologist91.991.0Nurses10.217.9Hospital pharmacy3.211.5Others5.33.6Does not remember1.20.8No information received0.81.7ConclusionsThe rheumatologist is the main source of information for patients on SC biological drugs. Nurses and hospital pharmacists are seldom mentioned, even though being very often visited for drug dispensing. Satisfaction with the information received is high, however nearly half said to have searched for information on the biological drug in alternative sources.AcknowledgementThis survey was financed by Merck Sharp &amp; Dohme of Spain and endorsed by the patient's association ConArtritis (Arthritis National Coordinator).Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkE1Lw0AQhhdRsFb_w4Ln1Nlsuk3w1PoNBUXredmPiU1ps3U3UXLzIv5Pf4nb1oNXYWCYmfedYR5CThkMGOPiTNW1n2O7slVIUmAiwXap_IALJvZIj2Uij20B-6QHADzJCjE6JEchLGIJOct75Gs8YQDZ98fnk2u9wUBdSe_q0vmVaipX0-eAluqOPsQS6ybQ96qZ08fN1dgx9LIKqEL0zTyqJmq386dWm7ZRNbo20Enllu6lMmpJZ3P0at0NtguSaVVilPo37I7JQamWAU9-c588X1_NLm6T6f3N3cV4mmiWjopEYMHZUKSpUlwbARy0tUNR6ixGZmHETcl1ihysVtYqKNORMUPIUo6FHea8T053e9fevbYYGrmIf9fxpGQFsDxPoSii6nynMt6F4LGUa1-tlO8kA7khL_-QlxvycktebshHt9i59WrxL-MPVM-SGw</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>de Toro, F.J.</creator><creator>Batlle, E.</creator><creator>González, C.M.</creator><creator>Cea-Calvo, L.</creator><creator>Pérez-Calvo, M.A.</creator><creator>Carmona, L.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey</title><author>de Toro, F.J. ; Batlle, E. ; González, C.M. ; Cea-Calvo, L. ; Pérez-Calvo, M.A. ; Carmona, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1279-6e9315622aa3bc6030bdd56fb4fb44d073cf3b2e30dbadda0f27cc50423e9d583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Toro, F.J.</creatorcontrib><creatorcontrib>Batlle, E.</creatorcontrib><creatorcontrib>González, C.M.</creatorcontrib><creatorcontrib>Cea-Calvo, L.</creatorcontrib><creatorcontrib>Pérez-Calvo, M.A.</creatorcontrib><creatorcontrib>Carmona, L.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Toro, F.J.</au><au>Batlle, E.</au><au>González, C.M.</au><au>Cea-Calvo, L.</au><au>Pérez-Calvo, M.A.</au><au>Carmona, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>1244</spage><epage>1245</epage><pages>1244-1245</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundAdequate information to patients on disease and therapies is important to improve lifestyle, adherence to treatments and outcomes.ObjectivesTo describe which are the main sources of information for patients with rheumatic diseases treated with subcutaneous (SC) biological drugs, which ones they consider relevant, and their satisfaction with the information received from the clinical team.MethodsRHEU-LIFE was a survey to patients &gt;18 years with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis treated with SC biological drugs, from 50 rheumatology outpatient clinics from Spain. The patients completed the survey anonymously at home. They selected from a list: 1) their sources of general information on disease (multiple choice), 2) the most important (one option), 3) who had informed them about the treatment alternatives (multiple choice) and 4) about the SC biological drug (multiple choice).ResultsThe survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years [SD 13.2], 42.4% men, 57.6% women). The main source of general information on disease was the rheumatologist (92.3%). Other sources mentioned were the primary care physician (21.7%), nurses (19.3%), medical websites (19.8%) or health related blogs (5.6%), brochures for patients (11.5%), friends or relatives (6.3%), patient associations (4.4%) or other patients (3.1%) and pharmacists (3.4%). Information about treatment options and the SC biological drug came mainly from the rheumatologist (&gt;90%) and infrequently from nurses or hospital pharmacists (Table). 46.1% mentioned having received only oral information, 6.0% only written and 45.2% both ways. Some 44.5% and 42.6% reported to be “very satisfied” and “satisfied” with the information received respectively, 10.6% “neither satisfied nor dissatisfied” and 2.1% and 0.2% “dissatisfied” or “very dissatisfied”. 45.2% alleged to search for information about the biological treatment in sources other than the hospital clinical staff.Sources of information mentioned by patients (multiple choice)General info about treatmentSpecific info about the biologic drug(%)(%)Rheumatologist91.991.0Nurses10.217.9Hospital pharmacy3.211.5Others5.33.6Does not remember1.20.8No information received0.81.7ConclusionsThe rheumatologist is the main source of information for patients on SC biological drugs. Nurses and hospital pharmacists are seldom mentioned, even though being very often visited for drug dispensing. Satisfaction with the information received is high, however nearly half said to have searched for information on the biological drug in alternative sources.AcknowledgementThis survey was financed by Merck Sharp &amp; Dohme of Spain and endorsed by the patient's association ConArtritis (Arthritis National Coordinator).Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2016-eular.3616</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1244-1245
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901882099
source BMJ Journals - NESLi2
title AB1004 Sources of Information Used by Patients with Rheumatic Diseases Treated with Subcutaneous Biological Therapy. Rheu-Life Survey
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A32%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB1004%E2%80%85Sources%20of%20Information%20Used%20by%20Patients%20with%20Rheumatic%20Diseases%20Treated%20with%20Subcutaneous%20Biological%20Therapy.%20Rheu-Life%20Survey&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=de%20Toro,%20F.J.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=1244&rft.epage=1245&rft.pages=1244-1245&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.3616&rft_dat=%3Cproquest_cross%3E4322516017%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901882099&rft_id=info:pmid/&rfr_iscdi=true